Literature DB >> 29782560

Adjuvant bevacizumab for resected non-small cell lung cancer: the end of an era?

Giannis Mountzios1.   

Abstract

Entities:  

Year:  2018        PMID： 29782560      PMCID： PMC5943215          DOI： 10.21037/tlcr.2018.03.24

Source DB:  PubMed          Journal:  Transl Lung Cancer Res        ISSN： 2218-6751


× No keyword cloud information.
  16 in total

1.  Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial.

Authors:  Jean-Yves Douillard; Rafael Rosell; Mario De Lena; Francesco Carpagnano; Rodryg Ramlau; Jose Luis Gonzáles-Larriba; Tomasz Grodzki; Jose Rodrigues Pereira; Alain Le Groumellec; Vito Lorusso; Claude Clary; Antonio J Torres; Jabrail Dahabreh; Pierre-Jean Souquet; Julio Astudillo; Pierre Fournel; Angel Artal-Cortes; Jacek Jassem; Leona Koubkova; Patricia His; Marcello Riggi; Patrick Hurteloup
Journal:  Lancet Oncol       Date:  2006-09       Impact factor: 41.316

2.  Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups.

Authors:  Gary M Strauss; James E Herndon; Michael A Maddaus; David W Johnstone; Elizabeth A Johnson; David H Harpole; Heidi H Gillenwater; Dorothy M Watson; David J Sugarbaker; Richard L Schilsky; Everett E Vokes; Mark R Green
Journal:  J Clin Oncol       Date:  2008-09-22       Impact factor: 44.544

3.  A phase 3 trial of bevacizumab in ovarian cancer.

Authors:  Timothy J Perren; Ann Marie Swart; Jacobus Pfisterer; Jonathan A Ledermann; Eric Pujade-Lauraine; Gunnar Kristensen; Mark S Carey; Philip Beale; Andrés Cervantes; Christian Kurzeder; Andreas du Bois; Jalid Sehouli; Rainer Kimmig; Anne Stähle; Fiona Collinson; Sharadah Essapen; Charlie Gourley; Alain Lortholary; Frédéric Selle; Mansoor R Mirza; Arto Leminen; Marie Plante; Dan Stark; Wendi Qian; Mahesh K B Parmar; Amit M Oza
Journal:  N Engl J Med       Date:  2011-12-29       Impact factor: 91.245

4.  Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial.

Authors:  Aimery de Gramont; Eric Van Cutsem; Hans-Joachim Schmoll; Josep Tabernero; Stephen Clarke; Malcolm J Moore; David Cunningham; Thomas H Cartwright; J Randolph Hecht; Fernando Rivera; Seock-Ah Im; György Bodoky; Ramon Salazar; Frédérique Maindrault-Goebel; Einat Shacham-Shmueli; Emilio Bajetta; Martina Makrutzki; Aijing Shang; Thierry André; Paulo M Hoff
Journal:  Lancet Oncol       Date:  2012-11-16       Impact factor: 41.316

Review 5.  Bevacizumab and micrometastases: revisiting the preclinical and clinical rollercoaster.

Authors:  Giannis Mountzios; George Pentheroudakis; Peter Carmeliet
Journal:  Pharmacol Ther       Date:  2013-09-27       Impact factor: 12.310

6.  Maintenance bevacizumab-pemetrexed after first-line cisplatin-pemetrexed-bevacizumab for advanced nonsquamous nonsmall-cell lung cancer: updated survival analysis of the AVAPERL (MO22089) randomized phase III trial.

Authors:  F Barlesi; A Scherpereel; V Gorbunova; R Gervais; A Vikström; C Chouaid; A Chella; J H Kim; M J Ahn; M Reck; A Pazzola; H T Kim; J G Aerts; C Morando; A Loundou; H J M Groen; A Rittmeyer
Journal:  Ann Oncol       Date:  2014-02-27       Impact factor: 32.976

7.  Randomized phase III trial of vinorelbine plus cisplatin compared with observation in completely resected stage IB and II non-small-cell lung cancer: updated survival analysis of JBR-10.

Authors:  Charles A Butts; Keyue Ding; Lesley Seymour; Philip Twumasi-Ankrah; Barbara Graham; David Gandara; David H Johnson; Kenneth A Kesler; Mark Green; Mark Vincent; Yvon Cormier; Glenwood Goss; Brian Findlay; Michael Johnston; Ming-Sound Tsao; Frances A Shepherd
Journal:  J Clin Oncol       Date:  2009-11-23       Impact factor: 44.544

8.  Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer.

Authors:  Giorgio Vittorio Scagliotti; Purvish Parikh; Joachim von Pawel; Bonne Biesma; Johan Vansteenkiste; Christian Manegold; Piotr Serwatowski; Ulrich Gatzemeier; Raghunadharao Digumarti; Mauro Zukin; Jin S Lee; Anders Mellemgaard; Keunchil Park; Shehkar Patil; Janusz Rolski; Tuncay Goksel; Filippo de Marinis; Lorinda Simms; Katherine P Sugarman; David Gandara
Journal:  J Clin Oncol       Date:  2008-05-27       Impact factor: 44.544

9.  Adjuvant chemotherapy with or without bevacizumab in patients with resected non-small-cell lung cancer (E1505): an open-label, multicentre, randomised, phase 3 trial.

Authors:  Heather A Wakelee; Suzanne E Dahlberg; Steven M Keller; William J Tester; David R Gandara; Stephen L Graziano; Alex A Adjei; Natasha B Leighl; Seena C Aisner; Jan M Rothman; Jyoti D Patel; Mark D Sborov; Sean R McDermott; Roman Perez-Soler; Anne M Traynor; Charles Butts; Tracey Evans; Atif Shafqat; Andrew E Chapman; Samer S Kasbari; Leora Horn; Suresh S Ramalingam; Joan H Schiller
Journal:  Lancet Oncol       Date:  2017-11-09       Impact factor: 41.316

10.  Adjuvant bevacizumab in patients with melanoma at high risk of recurrence (AVAST-M): preplanned interim results from a multicentre, open-label, randomised controlled phase 3 study.

Authors:  Pippa G Corrie; Andrea Marshall; Janet A Dunn; Mark R Middleton; Paul D Nathan; Martin Gore; Neville Davidson; Steve Nicholson; Charles G Kelly; Maria Marples; Sarah J Danson; Ernest Marshall; Stephen J Houston; Ruth E Board; Ashita M Waterston; Jenny P Nobes; Mark Harries; Satish Kumar; Gemma Young; Paul Lorigan
Journal:  Lancet Oncol       Date:  2014-04-15       Impact factor: 41.316
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.